Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
23 August 2022 - 1:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 15, 2022
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo Nordisk A/S – Share
repurchase programme
Bagsværd, Denmark, 15 August 2022 – On 3
August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European
Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe
Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during
a 12-month period beginning 2 February 2022.
Under the programme initiated 3 August 2022, Novo Nordisk will
repurchase B shares for an amount up to DKK 4.4 billion in the period from 4 August 2022 to 31 October 2022.
Since the announcement of the programme, the following transactions
have been made:
|
Number of
B shares |
Average
purchase price |
Transaction
value, DKK |
4 August 2022 |
90,000 |
774.61 |
69,715,134 |
5 August 2022 |
95,000 |
765.81 |
72,752,397 |
8 August 2022 |
90,000 |
752.63 |
67,736,306 |
9 August 2022 |
90,000 |
757.42 |
68,167,583 |
10 August 2022 |
90,000 |
768.12 |
69,131,058 |
11 August 2022 |
90,000 |
788.03 |
70,922,666 |
12 August 2022 |
90,000 |
783.09 |
70,478,526 |
Accumulated under the programme |
635,000 |
|
488,903,671 |
The details for each transaction made under the share repurchase programme
are published on novonordisk.com.
Page 2 of 2
Transactions related to Novo Nordisk’s incentive
programmes have resulted in a net transfer from Novo Nordisk of 29,214 B shares in the period from 4 August 2022 to 15 August 2022. The
shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of
18,253,211 B shares of DKK 0.20 as treasury shares, corresponding to 0.8% of the share capital. The total amount of A and B shares
in the company is 2,280,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK
24 billion during a 12- month period beginning 2 February 2022. As of 12 August 2022, Novo Nordisk has since 2 February 2022
repurchased a total of 16,542,432 B shares at an average share price of DKK 767.16 per B share equal to a transaction value of DKK
12,690,672,532
Novo Nordisk is a leading global healthcare company,
founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such
as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines,
and working to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets its products
in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock
Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Further information
Media: |
|
|
Ambre Brown Morley |
+45 3079 9289 |
abmo@novonordisk.com |
Natalia Salomao Abrahao (US) |
+1 848 304 1027 |
niaa@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
David Heiberg Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
Jacob Martin Wiborg Rode |
+45 3075 5956 |
jrde@novonordisk.com |
Mark Joseph Root (US) |
+1 848 213 3219 |
mjhr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
|
|
Company announcement No 65 / 2022 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: August 15, 2022 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024